A GIP/GLP-1/glucagon triple agonist against a long-acting amylin analogue: why they are not like-for-like alternatives, what REDEFINE 1 showed for cagrilintide alone, and a map of retatrutide alternatives. No head-to-head results exist. Research use only.

Retatrutide vs CagriSema: one triple agonist vs a two-molecule combination

One three-receptor peptide against Novo Nordisk’s cagrilintide + semaglutide combination: how the two programmes count weight loss (treatment-policy vs trial-product estimands), where each stands with regulators, and what is available as a research compound. Research use only.

Retatrutide vs MariTide: weekly triple agonist vs monthly GIP antagonist

A weekly peptide that activates GIP, GLP-1 and glucagon receptors against Amgen’s monthly antibody conjugate that activates GLP-1 and blocks GIP: the GIP question, the Phase 2 data and why MariTide is not available as a research compound. Research use only.

Retatrutide vs amycretin: triple agonist vs single-molecule amylin + GLP-1

A GIP/GLP-1/glucagon triple agonist against Novo Nordisk’s amylin + GLP-1 agonist, in injectable and oral form: what the early-phase and diabetes-population data do and do not show. No head-to-head results exist. Research use only.

Retatrutide vs survodutide: two glucagon-arm agonists, one with GIP

Both pair GLP-1 with glucagon; retatrutide adds GIP. Separately reported weight data, survodutide’s MASH programme and why cross-trial numbers cannot say what the GIP arm adds. No head-to-head results exist. Research use only.

What is Mazdutide? GLP-1/Glucagon Research Guide

Mazdutide (IBI362 / LY3305677) is a GLP-1 and glucagon dual receptor agonist in late-stage trials in China. The mechanism, the DREAMS trial data, how it compares to tirzepatide and retatrutide, and its regulatory status. Research use only.

Best Peptides for Weight Loss Research (2026): The GLP-1 Compounds Labs Actually Study

The compounds that dominate weight-loss research - retatrutide (triple agonist), tirzepatide, semaglutide and cagrilintide, plus the GH-axis veteran tesamorelin and the HGH fragment AOD-9604. Ranked by mechanism and reported trial data, honest about what is approved versus investigational and where AOD-9604 fell short. Research use only.

Trump, Retatrutide and the Obesity-Drug Demand Story

The White House denies that Donald Trump got early compassionate-use access to retatrutide, an experimental obesity drug still in Eli Lilly trials. What the story says, what compassionate use is, why retatrutide is not approved before 2027, and why research use only is a separate category from human use.

The Half-Life Arms Race: Why Peptides Are Engineered to Last

Nearly every modern peptide program is, underneath, a half-life-engineering project - acylation, PEGylation, Fc fusion, once-weekly to once-monthly. A field map of that arms race, and the near-empty frontier it leaves behind: designing for rhythm, not duration. Research use only.

Beyond GLP-1: Amylin, Glucagon, GIP and the Next Obesity Research Wave

Obesity research has moved past GLP-1 alone. This hub maps the next-generation mechanisms - GIP agonism and antagonism, glucagon, and amylin - and the candidate landscape from tirzepatide and retatrutide to MariTide, CagriSema, survodutide, amycretin and petrelintide. Research use only.

Orforglipron: a research guide to the first oral non-peptide GLP-1

Eli Lilly's once-daily oral small-molecule GLP-1 receptor agonist - not a peptide. Mechanism, the ATTAIN Phase 3 data (~12.4% at 72 weeks), why a pill changes access, and how it differs from the research peptides. Research use only.

MariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1/GIP Research Profile

Amgen's once-monthly peptide-antibody conjugate pairs GLP-1 agonism with GIP antagonism - the unusual mechanism, the Phase 2 data (up to ~20%), and where it sits in the obesity pipeline. Research use only.

CagriSema & Cagrilintide: The Amylin + GLP-1 Combo Explained

Novo Nordisk's combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist) - the mechanism, the REDEFINE Phase 3 data (~20-23%), and why amylin is the next obesity-research mechanism. Research use only.

Amycretin: Novo Nordisk's GLP-1 and Amylin Candidate Explained

Novo Nordisk's investigational single-molecule GLP-1 and amylin receptor agonist in oral and injectable development - the science, the early data (~22% injectable at 36 weeks), and how it compares to CagriSema. Research use only.

Survodutide: GLP-1, Glucagon and the MASH Opportunity

Boehringer Ingelheim's investigational GLP-1 / glucagon dual agonist studied for obesity and MASH - the mechanism, the SYNCHRONIZE program, the ~16.6% Phase 3 weight loss, and the distinctive liver-fat angle. Research use only.

Petrelintide: Zealand and Roche's Amylin Analogue Explained

Zealand Pharma and Roche's investigational long-acting amylin analogue - the amylin-first obesity strategy, the Phase 2 data (~10.7% at week 42), and why an amylin-only approach matters. Research use only.

Research use only. These articles summarise public literature and catalogue facts. They do not diagnose, treat, or prevent any disease, and are not medical advice.

Browse the full catalogue

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research